Pricing Platform Skills Contact
Free · No signup required

Evidence retrieved in 90 seconds.
Staged for review in minutes.

Rapid Scan retrieves from 16 public biomedical sources, extracts metadata, and builds a review-ready brief — all at no cost.

16 sources
Biomedical databases queried in parallel
60–90s
Time from query to structured brief
$0
No API key, no account, no queue
What it does

From question to evidence brief in three actions

One query triggers retrieval, extraction, and structured output across every relevant database simultaneously.

Retrieve

Pull public evidence from PubMed, ClinicalTrials.gov, FAERS, and 13 other biomedical sources simultaneously — no manual searching required.

Structure

Organize findings into review-ready outputs with PICO extraction, source attribution, evidence classification, and gaps clearly noted.

Stage

Track provenance, citation chain, and review status so teams always know what is retrieved, drafted, or pending expert sign-off.

How it works

Three steps from question to staged brief

1
Enter your query

Type your clinical question in plain English — PICO structure is generated automatically and shown for review before any search runs.

2
Review sources

Results arrive from 16 databases in parallel with source attribution and evidence classification; anything it cannot source is flagged.

3
Export brief

Download a structured evidence brief. Human review declaration required before any external or decision use.

Included free

No limits on what
you can explore

Everything in Rapid Scan is free — no account, no API key, no usage cap. The full product starts with zero friction.

Automated abstract screening across PubMed, Europe PMC, ClinicalTrials.gov
AI-assisted PICO extraction — shown to you for review before results finalize
Key findings summary with evidence gaps explicitly documented
PMID citations on sourced findings — unverified claims flagged
Immediate output — no queue, no wait, no credit card
Example output · ALS & Riluzole

"What does the literature say about riluzole efficacy in ALS patients with late-stage disease?"

Riluzole prolongs median survival by about 2–3 months vs. placebo, pooled across 4 RCTs (PMID: 22419278)
Effect attenuates in older, more advanced patients — pooled HR 0.84 (95% CI 0.70–1.00) once that trial is included (PMID: 22419278)
No RCT evidence for initiation beyond 18 months post-diagnosis — evidence gap noted
FAERS: hepatic events reported, consistent with the label's Hepatic Injury warning — drug-induced liver injury, some fatal, plus asymptomatic transaminase elevations; aminotransferase monitoring required
Retrieved from 16 databases · 90s · Citations carry source IDs
Important

Rapid Scan output is for research use only. Human review required before external or decision use. Not a medical device. Association is never presented as causation. Citations carry a PMID, NCT ID, or FAERS reference; claims that cannot be sourced are flagged.

Ready to run your first scan?

Free, no signup, results in 90 seconds. Full Systematic Review available on the platform.